IDH2 and acute myeloid leukemia: IDH inhibitors have shown good clinical response in AML patients and enasidenib and ivosidenib are approved by Food and Drug Administration (FDA) in 2017 and 2018 for the treatment of adult relapsed or refractory (R/R) AML with IDH2 and IDH1 mutations, respectively [17].